We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
3 Apr 2023 - Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of […]
Read morePolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
14 Mar 2023 - Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]
Read moreCEO of PolyPeptide resigns
30 Jan 2023 - Baar, 30 January 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the resignation by […]
Read morePolyPeptide signs significant commercial agreement
19 Dec 2022 - Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a […]
Read morePolyPeptide provides market update
2 Dec 2022 - Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update. […]
Read morePolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
19 Aug 2022 - PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligo-nucleotide-based active pharmaceutical ingredients, today announced its detailed results for the first half of […]
Read morePolyPeptide provides market update
12 Jul 2022 - The EBITDA margin for the first half of 2022 is expected to be around 20% of revenue. Media Release – ad hoc announcement pursuant to Art. […]
Read morePolyPeptide achieves strong profitable growth in 2021
15 Mar 2022 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the financial year 2021: Revenue growth of […]
Read morePolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
1 Dec 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Neil Thompson as Director Global Sales and Marketing and member […]
Read more